Yang, Chongzhe published the artcileTherapeutic potential of tricarboxylic acid cycle metabolite itaconate in cardiovascular diseases, Application In Synthesis of 617-52-7, the publication is EBioMedicine (2020), 102938, database is CAplus and MEDLINE.
Tricarboxylic acid cycle (TCA cycle) produces metabolites in the mitochondria under various pathophysiol. conditions. LPS and interferons induce IRG1 expression and itaconate production from the TAC cycle. Itaconate and its derivatives DI and OI contribute to (1) succinate dehydrogenase inhibition and succinate accumulation; (2) KEAP1 cysteine alkylation, Nrf2 expression and nucleus translocation, and pro- and anti-inflammatory mol. expression regulation; (3) ATF3 expression; and (4) M2 macrophage polarization. Adeno-associated virus (AAV)-mediated overexpression of Nrf2 reduced AAA growth and lesion inflammation, but shRNA-mediated Nrf2 knockdown revealed the opposite phenotypes. Instead of using the Irg1 mice to test a role for itaconate in AAA, this study used AAV-mediated KEAP1 overexpression to increase AAA growth and lesion inflammation. OI treatment reversed these KEAP1 adverse activities, likely via KEAP1 alkylation and disassocn. from Nrf2, although this study did not explore the details. This is the first study of TCA cycle metabolites in AAA that extends the concept of using OI or DI as a therapeutic regimen to slow murine and human AAA growth and associated lesion and systemic inflammation. The demonstrated beneficial effects of OI and DI in sepsis, hepatic, cerebral, and cardiac IR injuries support this potential.
EBioMedicine published new progress about 617-52-7. 617-52-7 belongs to esters-buliding-blocks, auxiliary class Alkenyl,Aliphatic hydrocarbon chain,Ester, name is Dimethyl itaconate, and the molecular formula is C6H4ClNO2, Application In Synthesis of 617-52-7.
Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics